AV
AVCRF.US Avricore Health Inc
- Market cap
- USD 101K
- P/E
- -
- P/B
- 0.13x
- ROE
- -217.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is AVCRF.US undervalued?
Graham numberThe Graham number of Avricore Health Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Avricore Health Inc fundamental analysis
No fundamental analysis for Avricore Health Inc yet.
Avricore Health Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Avricore Health Inc
Avricore Health Inc. engages in the health data and point-of-care technologies businesses in Canada and the United Kingdom. It provides HealthTab, a turnkey point-of-care testing platform for pharmacies that can test up to 27 biomarkers on the spot for screening and managing chronic conditions, such as diabetes. The company was formerly known as Vanc Pharmaceuticals Inc. and changed its name to Avricore Health Inc. in October 2018. Avricore Health Inc. was founded in 1996 an…
Full company profileAvricore Health Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Avricore Health Inc annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.01M | 538K | 226K | 33.0K | 33.0K | 123K | 1.77M | 3.49M | 4.79M | 533K | 217K |
| Gross Profit | 303K | 247K | 38.1K | 14.5K | 17.5K | 30.5K | 457K | 1.20M | 1.88M | 236K | -8.43K |
| Operating Income | -2.33M | -1.99M | -2.88M | -1.60M | -859K | -1.75M | -810K | -687K | 182K | -1.37M | -1.36M |
| EBITDA | -2.61M | -2.76M | -2.93M | -1.42M | -896K | -1.73M | -635K | -281K | 629K | -1.23M | -1.34M |
| Net Income | -2.61M | -3.49M | -5.39M | -2.11M | -1.33M | -1.75M | -827K | -701K | -669K | -1.86M | -2.42M |
| EPS | -0.18 | -0.19 | -0.16 | -0.04 | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 |
| Balance Sheet | |||||||||||
| Total Assets | 2.28M | 2.90M | 1.20M | 208K | 440K | 2.28M | 2.57M | 2.54M | 2.30M | 563K | 1.24M |
| Total Liabilities | 357K | 402K | 314K | 674K | 1.15M | 84.5K | 605K | 529K | 331K | 173K | 129K |
| Shareholders' Equity | 1.92M | 2.50M | 886K | -465K | -714K | 2.20M | 1.96M | 2.01M | 1.97M | 389K | 1.11M |
| Cash & Short-term Investments | 427K | 560K | 84.4K | 13.8K | 303K | 2.01M | 631K | 287K | 1.14M | 238K | 923K |
| Total Debt | - | - | - | 21.4K | 1.00M | 40.0K | 40.0K | 40.0K | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.06M | -1.77M | -1.73M | -686K | -1.22M | -1.23M | -438K | 660K | 1.00M | -789K | -1.52M |
| Capital Expenditure | 6.34K | 3.78K | 55.0K | 105K | 105K | 140K | 1.20M | 1.05M | 205K | 88.4K | 8.68K |
| Free Cash Flow | -2.07M | -1.77M | -1.78M | -686K | -1.22M | -1.37M | -1.64M | -386K | 799K | -878K | -1.52M |
| Ratios | |||||||||||
| ROE | -136.3% | -139.6% | -608.6% | - | - | -79.5% | -42.1% | -34.9% | -34.0% | -477.1% | -217.8% |
| ROA | -114.9% | -120.2% | -449.2% | -1,013.8% | -302.9% | -76.6% | -32.2% | -27.6% | -29.1% | -330.1% | -195.1% |
| Net Profit Margin | -257.9% | -648.4% | -2,381.0% | -6,402.6% | -4,035.5% | -1,422.2% | -46.7% | -20.1% | -14.0% | -348.2% | -1,113.7% |
| Debt to Equity | - | - | - | - | - | 0.02x | 0.02x | 0.02x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Avricore Health Inc dividends
Avricore Health Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:4 on Nov 21, 2016.
Who owns Avricore Health Inc
- Insiders 9.27%
- Institutions 0.00%
- Public & others 90.73%
- Shares outstanding 126M
- Free float 115M
Avricore Health Inc company profile
- Company name
- Avricore Health Inc
- Ticker
- AVCRF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 700 ? 1199 West Hastings Street, Vancouver, BC, Canada, V6E 3T5
- Phone
- 778 968 1176
- Website
- avricore.com
About Avricore Health Inc
Avricore Health Inc. engages in the health data and point-of-care technologies businesses in Canada and the United Kingdom. It provides HealthTab, a turnkey point-of-care testing platform for pharmacies that can test up to 27 biomarkers on the spot for screening and managing chronic conditions, such as diabetes. The company was formerly known as Vanc Pharmaceuticals Inc. and changed its name to Avricore Health Inc. in October 2018. Avricore Health Inc. was founded in 1996 and is based in Vancouver, Canada.
Avricore Health Inc management
3- Mr. Rodger SeccombeCEO, CTO & Director · born 1981
- Ms. Kiriaki Smith CPA, CFO, CGACFO & Corporate Secretary · born 1967
- Mr. Will SeccombeCommunications Advisor